• Je něco špatně v tomto záznamu ?

Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial

JD. Grainger, F. Locatelli, T. Chotsampancharoen, E. Donyush, B. Pongtanakul, P. Komvilaisak, D. Sosothikul, G. Drelichman, N. Sirachainan, S. Holzhauer, V. Lebedev, R. Lemons, D. Pospisilova, U. Ramenghi, JB. Bussel, KK. Bakshi, M. Iyengar, GW....

. 2015 ; 386 (10004) : 1649-58. [pub] 20150728

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky kontrolované, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16010016
E-zdroje Online Plný text

NLK ProQuest Central od 1992-01-04 do Před 3 měsíci
Nursing & Allied Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Health & Medicine (ProQuest) od 1992-01-04 do Před 3 měsíci
Family Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Psychology Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Health Management Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Public Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci

Odkazy

PubMed 26231455
DOI 10.1016/s0140-6736(15)61107-2
Knihovny.cz E-zdroje

BACKGROUND: The thrombopoietin receptor agonist eltrombopag has been shown to be safe, tolerable, and effective for adults with chronic immune thrombocytopenia. We aimed to investigate the safety and efficacy of eltrombopag for children with chronic immune thrombocytopenia. METHODS: PETIT2 was a two part, randomised, multicentre, placebo-controlled study done at 38 centres in 12 countries (Argentina, Czech Republic, Germany, Hong Kong, Israel, Italy, Russia, Spain, Taiwan, Thailand, UK, and USA). Paediatric patients aged 1-17 years who had chronic immune thrombocytopenia and platelet counts less than 30 × 10(9) per L were randomly assigned (2:1) to receive eltrombopag or placebo. We stratified patients by age into three cohorts (patients aged 12-17 years, 6-11 years, and 1-5 years) before randomly entering them into a 13 week, double-blind period. Randomisation was done by the GlaxoSmithKline Registration and Medication Ordering System and both patients and study personnel were masked to treatment assignments. Patients who were allocated eltrombopag received tablets (except for those aged 1-5 years who received an oral suspension formulation) once per day for 13 weeks. Starting doses for patients aged 6-17 were based on bodyweight, and ethnic origin and ranged between 50 mg/day and 25 mg/day (starting dose for patients aged 1-5 years was 1·2 mg/kg/day or 0·8 mg/kg/day for east Asian patients). Patients who completed the double-blind period entered a 24 week open-label treatment period in which all patients received eltrombopag at either the starting dose (if they were formerly on placebo) or their established dose. The primary outcome was the proportion of patients achieving platelet counts of at least 50 × 10(9) per L in the absence of rescue therapy for 6 or more weeks from weeks 5 to 12 of the double-blind period. The intention-to-treat population included in the efficacy assessment consisted of all patients who were randomly assigned to one of the treatment groups, and the safety population included all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT01520909. FINDINGS: Beginning in March 15, 2012, 92 patients were enrolled, and the trial was completed on Jan 2, 2014. 63 patients were assigned to receive eltrombopag and 29 were assigned to receive placebo. In the double-blind period, three patients discontinued treatment because of adverse events: two patients in the eltrombopag group withdrew because of increased liver aminotransferases and one in the placebo group withdrew because of abdominal haemorrhage. 25 (40%) patients who received eltrombopag compared with one (3%) patient who received placebo achieved the primary outcome of platelet counts of at least 50 × 10(9) per L for 6 of the last 8 weeks of the double-blind period (odds ratio 18·0, 95% CI, 2·3-140·9; p=0·0004). Responses were similar in all cohorts (eltrombopag vs placebo: 39% vs 10% for patients aged 12-17 years, 42% vs 0% for patients aged 6-11 years, and 36% vs 0% for patients aged 1-5 years). Proportionately fewer patients who received eltrombopag (23 [37%] of 63 patients) had WHO grades 1-4 bleeding at the end of the double-blind period than did those who received placebo (16 [55%] of 29 patients); grades 2-4 bleeding were similar (three [5%] patients who received eltrombopag vs two [7%] patients who received placebo). During the 24-week open-label treatment period, 70 [80%] of 87 patients achieved platelet counts of 50 × 10(9) per L or more at least once. Adverse events that occurred more frequently with eltrombopag than with placebo included nasopharyngitis (11 [17%] patients), rhinitis (10 [16%] patients), upper respiratory tract infection (7 [11%] patients), and cough (7 [11%] patients). Serious adverse events occurred in five (8%) patients who received eltrombopag and four (14%) who received placebo. Safety was consistent between the open-label and double-blind periods. No deaths, malignancies, or thromboses occurred during the trial. INTERPRETATION: Eltrombopag, which produced a sustained platelet response in 40% of patients with chronic immune thrombocytopenia, is a suitable therapeutic option for children with chronic symptomatic immune thrombocytopenia. We identified no new safety concerns and few patients discontinued treatment because of adverse events. FUNDING: GlaxoSmithKline.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010016
003      
CZ-PrNML
005      
20160415110005.0
007      
ta
008      
160408s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S0140-6736(15)61107-2 $2 doi
024    7_
$a 10.1016/S0140-6736(15)61107-2 $2 doi
035    __
$a (PubMed)26231455
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Grainger, John D $u Department of Haematology, Royal Manchester Children's Hospital, University of Manchester, Manchester, UK; Central Manchester Hospitals NHS Foundation Trust, NIHR/Wellcome Trust Manchester CRF, Royal Manchester Children's Hospital, University of Manchester, Manchester, UK.
245    10
$a Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial / $c JD. Grainger, F. Locatelli, T. Chotsampancharoen, E. Donyush, B. Pongtanakul, P. Komvilaisak, D. Sosothikul, G. Drelichman, N. Sirachainan, S. Holzhauer, V. Lebedev, R. Lemons, D. Pospisilova, U. Ramenghi, JB. Bussel, KK. Bakshi, M. Iyengar, GW. Chan, KD. Chagin, D. Theodore, LM. Marcello, CK. Bailey,
520    9_
$a BACKGROUND: The thrombopoietin receptor agonist eltrombopag has been shown to be safe, tolerable, and effective for adults with chronic immune thrombocytopenia. We aimed to investigate the safety and efficacy of eltrombopag for children with chronic immune thrombocytopenia. METHODS: PETIT2 was a two part, randomised, multicentre, placebo-controlled study done at 38 centres in 12 countries (Argentina, Czech Republic, Germany, Hong Kong, Israel, Italy, Russia, Spain, Taiwan, Thailand, UK, and USA). Paediatric patients aged 1-17 years who had chronic immune thrombocytopenia and platelet counts less than 30 × 10(9) per L were randomly assigned (2:1) to receive eltrombopag or placebo. We stratified patients by age into three cohorts (patients aged 12-17 years, 6-11 years, and 1-5 years) before randomly entering them into a 13 week, double-blind period. Randomisation was done by the GlaxoSmithKline Registration and Medication Ordering System and both patients and study personnel were masked to treatment assignments. Patients who were allocated eltrombopag received tablets (except for those aged 1-5 years who received an oral suspension formulation) once per day for 13 weeks. Starting doses for patients aged 6-17 were based on bodyweight, and ethnic origin and ranged between 50 mg/day and 25 mg/day (starting dose for patients aged 1-5 years was 1·2 mg/kg/day or 0·8 mg/kg/day for east Asian patients). Patients who completed the double-blind period entered a 24 week open-label treatment period in which all patients received eltrombopag at either the starting dose (if they were formerly on placebo) or their established dose. The primary outcome was the proportion of patients achieving platelet counts of at least 50 × 10(9) per L in the absence of rescue therapy for 6 or more weeks from weeks 5 to 12 of the double-blind period. The intention-to-treat population included in the efficacy assessment consisted of all patients who were randomly assigned to one of the treatment groups, and the safety population included all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT01520909. FINDINGS: Beginning in March 15, 2012, 92 patients were enrolled, and the trial was completed on Jan 2, 2014. 63 patients were assigned to receive eltrombopag and 29 were assigned to receive placebo. In the double-blind period, three patients discontinued treatment because of adverse events: two patients in the eltrombopag group withdrew because of increased liver aminotransferases and one in the placebo group withdrew because of abdominal haemorrhage. 25 (40%) patients who received eltrombopag compared with one (3%) patient who received placebo achieved the primary outcome of platelet counts of at least 50 × 10(9) per L for 6 of the last 8 weeks of the double-blind period (odds ratio 18·0, 95% CI, 2·3-140·9; p=0·0004). Responses were similar in all cohorts (eltrombopag vs placebo: 39% vs 10% for patients aged 12-17 years, 42% vs 0% for patients aged 6-11 years, and 36% vs 0% for patients aged 1-5 years). Proportionately fewer patients who received eltrombopag (23 [37%] of 63 patients) had WHO grades 1-4 bleeding at the end of the double-blind period than did those who received placebo (16 [55%] of 29 patients); grades 2-4 bleeding were similar (three [5%] patients who received eltrombopag vs two [7%] patients who received placebo). During the 24-week open-label treatment period, 70 [80%] of 87 patients achieved platelet counts of 50 × 10(9) per L or more at least once. Adverse events that occurred more frequently with eltrombopag than with placebo included nasopharyngitis (11 [17%] patients), rhinitis (10 [16%] patients), upper respiratory tract infection (7 [11%] patients), and cough (7 [11%] patients). Serious adverse events occurred in five (8%) patients who received eltrombopag and four (14%) who received placebo. Safety was consistent between the open-label and double-blind periods. No deaths, malignancies, or thromboses occurred during the trial. INTERPRETATION: Eltrombopag, which produced a sustained platelet response in 40% of patients with chronic immune thrombocytopenia, is a suitable therapeutic option for children with chronic symptomatic immune thrombocytopenia. We identified no new safety concerns and few patients discontinued treatment because of adverse events. FUNDING: GlaxoSmithKline.
650    _2
$a mladiství $7 D000293
650    _2
$a benzoáty $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D001565
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a chronická nemoc $7 D002908
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a hydraziny $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D006834
650    _2
$a kojenec $7 D007223
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a počet trombocytů $7 D010976
650    _2
$a idiopatická trombocytopenická purpura $x farmakoterapie $7 D016553
650    _2
$a pyrazoly $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D011720
650    _2
$a receptory thrombopoetinu $x agonisté $7 D053628
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky kontrolované $7 D018848
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Locatelli, Franco $u IRCCS Ospedale Pediatrico Bambino Gesú, University of Pavia, Rome, Italy.
700    1_
$a Chotsampancharoen, Thirachit $u Prince of Songkla University, Songklanagarind Hospital, Bangkok, Thailand.
700    1_
$a Donyush, Elena $u Izmaylovskaya Children's City Clinical Hospital, Moscow Board of Health, Moscow, Russia.
700    1_
$a Pongtanakul, Bunchoo $u Siriraj Hospital, Bangkok, Thailand.
700    1_
$a Komvilaisak, Patcharee $u Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand.
700    1_
$a Sosothikul, Darintr $u Chulalongkorn University, Bangkok, Thailand.
700    1_
$a Drelichman, Guillermo $u Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina.
700    1_
$a Sirachainan, Nongnuch $u Ramathibodi Hospital, Bangkok, Thailand.
700    1_
$a Holzhauer, Susanne $u Charité, University Medicine, Berlin, Germany.
700    1_
$a Lebedev, Vladimir $u GUZ Regional Children's Clinical Hospital, Krasnodar, Russia.
700    1_
$a Lemons, Richard $u Primary Children's Medical Center, Salt Lake City, UT, USA.
700    1_
$a Pospisilova, Dagmar $u Faculty Hospital of Palacky University, Olomouc, Czech Republic.
700    1_
$a Ramenghi, Ugo $u Regina Margherita Children's Hospital, Turin, Italy.
700    1_
$a Bussel, James B $u Weill Cornell Medical College, New York, NY, USA.
700    1_
$a Bakshi, Kalpana K $u GlaxoSmithKline, Collegeville, PA, USA.
700    1_
$a Iyengar, Malini $u GlaxoSmithKline, Collegeville, PA, USA.
700    1_
$a Chan, Geoffrey W $u GlaxoSmithKline, Collegeville, PA, USA.
700    1_
$a Chagin, Karen D $u GlaxoSmithKline, Collegeville, PA, USA.
700    1_
$a Theodore, Dickens $u GlaxoSmithKline, Research Triangle Park, NC, USA.
700    1_
$a Marcello, Lisa M $u GlaxoSmithKline, Collegeville, PA, USA.
700    1_
$a Bailey, Christine K $u GlaxoSmithKline, Collegeville, PA, USA.
773    0_
$w MED00010161 $t Lancet (London, England) $x 1474-547X $g Roč. 386, č. 10004 (2015), s. 1649-58
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26231455 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20160415110050 $b ABA008
999    __
$a ok $b bmc $g 1113445 $s 934384
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 386 $c 10004 $d 1649-58 $e 20150728 $i 1474-547X $m Lancet $n Lancet $x MED00010161
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Možnosti archivace